ChemicalBook > CAS DataBase List > Deferoxamine

Deferoxamine

Product Name
Deferoxamine
CAS No.
70-51-9
Chemical Name
Deferoxamine
Synonyms
DESFEROXAMINE;dfoa;taone;entaone;ba33112;desferin;desferex;desferan;ba-29837;ba-33112
CBNumber
CB8506290
Molecular Formula
C25H48N6O8
Formula Weight
560.69
MOL File
70-51-9.mol
More
Less

Deferoxamine Property

Melting point:
139°C
Boiling point:
627.9°C (rough estimate)
Density 
1.2216 (rough estimate)
refractive index 
1.5540 (estimate)
pka
9.08±0.50(Predicted)
form 
Solid
color 
White to off-white
EPA Substance Registry System
Deferoxamine (70-51-9)
More
Less

Safety

Hazardous Substances Data
70-51-9(Hazardous Substances Data)
Toxicity
LD50 oral in mouse: 1340mg/kg
More
Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Warning
Hazard statements

H317May cause an allergic skin reaction

Precautionary statements

P261Avoid breathing dust/fume/gas/mist/vapours/spray.

P272Contaminated work clothing should not be allowed out of the workplace.

P280Wear protective gloves/protective clothing/eye protection/face protection.

P302+P352IF ON SKIN: wash with plenty of soap and water.

P321Specific treatment (see … on this label).

P333+P313IF SKIN irritation or rash occurs: Get medical advice/attention.

P363Wash contaminated clothing before reuse.

P501Dispose of contents/container to..…

More
Less

N-Bromosuccinimide Price

American Custom Chemicals Corporation
Product number
API0015199
Product name
DEFEROXAMINE
Purity
95.00%
Packaging
5MG
Price
$500.04
Updated
2021/12/16
American Custom Chemicals Corporation
Product number
API0015199
Product name
DEFEROXAMINE
Purity
95.00%
Packaging
1G
Price
$1428
Updated
2021/12/16
More
Less

Deferoxamine Chemical Properties,Usage,Production

Description

Deferoxamine was introduced in the 1960s for chelation of iron. It is synthesized by removing a central iron molecule from ferrioxamine B, a compound obtained from the microorganism Streptomyces pilosus. Deferoxamine binds to iron from ferritin and forms ferrioxamine, a very stable and water-soluble chelate with a characteristic reddish color.

Originator

Deferoxamine,Novartis,Germany

Uses

Deferoxamine is used for the treatment of both acute iron intoxication and chronic iron overload due to transfusiondependent anemias. It has also been used in trials for malaria treatment and for aluminum chelation in hemodialysis patients. Studies of a rat model of intracerebral hemorrhage have noted that deferoxamine treatment reduced oxidative stress from iron release, indicating a possible role in preventing damage associated with hemorrhagic strokes.

Uses

Chelating agent (iron).

Definition

ChEBI: Desferrioxamine B is an acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator. It has a role as an iron chelator, a siderophore, a ferroptosis inhibitor and a bacterial metabolite. It is a conjugate acid of a desferrioxamine B(3-).

Manufacturing Process

O-Benzylhydroxylamine hydrochloride (4.7 g, 29.7 mmol) was mixed with 5 ml of water and 11 ml of methanol at 0°C and the pH adjusted to 4.7 using 6 N KOH. The aldehyde, 4-cyanobutanal (2.6 mL, 27 mmol) was added to the hydroxylamine and the mixture allowed to warm to room temperature. The pH was maintained by addition of further 6 N KOH. After 1 h, the reaction was cooled to 0°C, and sodium cyanoborohydride (1.26 g, 20 mmol) was added. The pH was adjusted to 3 and maintained by addition of saturated HCl in methanol. When the pH stabilized, the reaction was warmed to room temperature and stirred for 3 h at a PH of 3. The reaction mixture was then poured into ether and made basic with 6 N KOH. The aqueous layer was extracted with ether (3x50 mL). The extracts were combined, washed with brine, and dried over magnesium sulfate. The solvents were removed and the resulting liquid distilled at 150°-151°C (0.6 mm) to give 4.65 g (84% of Obenzyl-N-(4-cyanobutyl)hydroxylamine. 2.8 g (13.7 mmol) of the above prepared hydroxylamine in 23 ml of pyridine and 2.1 g (20.8 mmol) of succcinic anhydride, initially heated at 100°C for 1.5 h then allowed to cool to room temperature and stirred overnight. The pyridine was removed in vacuum and the residue was dissolved in a minimal amount of chloroform, and the residue was dissolved in ether, which was extracted three times with 20% potassium bicarbonate (3x50 mL). The aqueous solutions were combined, acidified, extracted with ether, dried, filtered and evaporated; the residue was then chromotagraphed on silica gel to give 4.12 g (98%) of N-(4-cyanobutylN-(benzyloxy)succinamic acid.
2.6 g (12.75 mmol) of O-benzyl-N-(4-cyanobutyl)hydroxylamine, 17.24 mL of pyridine and 17.2 mL of acetic anhydride were stirred under argon at room temperature for 24 h. Then the excess pyridine and acetic acid anhydride were removed by vacuum. The resulting oil was taken up in chloroform, which was extracted with 1 N HCl (2x50mL), washed with sodium bicarbonate and brine, dried, over sodium sulfate, filtered and evaporated to give 3.4 g (100%) of N-(4-cyanobutyl)-N-(benzyloxy)acetamide as a light oil. 1.4 g (5.7 mmol) of this product, 2.6 g Raney nickel, 15 ml of ammonia saturated methanol and 4 ml of saturated ammonium hydroxide were cooled in a ice bath and anhydrous ammonia was allowed to bubble through the solution for 10 min. The bottle was pressurized to 50 psi with hydrogen and shook for 3 h. Then the catalyst was filtered and the solvents evaporated. The crude material was chromatografed on silica gel to gave a 1.25 g (88%) of N-(5- aminopentyl)-N-(benzyloxy)acetamide.
1 g (4 mmol), of the above acetamide, 1.46 g (4.79 mmol) of N-(4- cyanobutyl-N-(benzyloxy)succinamic acid, 1.24 g (6 mmol) of DCC and 70 mg of DMAP was cooled to 0°C for 0.55 h in 28 mL of chloroform. The mixture was allowed to warm to room temperature and stirred 24 h. Then it was again cooled to 0°C, filtered and chromatografed to yield 2.1 g (98%) of N-(4- cyanobutyl)-3-[{5-N-benzyloxy)acetamido)pentyl}carbomoyl]-Obenzylpropionohydroxamic acid. This product (1 g) was hydrogeneted by analogue with N-(4-cyanobutyl)-N-(benzyloxy)acetamide using Nickel Raney as catalyst to give 1 g (88%) N-(5-aminopentyl)-3-[{5-(N - benzyloxyacetamido)pentyl}carbomoyl]-O-benzylpropionohydroxamic acid, which produced by the reaction with DCC described above 0.78 g (88%) of N- [5-[3-[{4-cyanobutyl)(benzyloxy)-carbomoyl]propionaminoamido]pentyl}-3- [{5-(N-bebzyloxyacetamido)pentyl]-carbomoyl]-O-benzylpropionohydroxamic acid. The purity of all products confirmed with1H-NMR and elemental analyses. The last compound (0.165 g, 0.2 mmol) was reduced in methanol, 2.7 mL of 0.1 N HCl and 0.27 g of 10% Pd on C. The hydrogenation was carried out at one atmosphere of hydrogene for 7.5 hrs. The solution was filtered, the solvents were removed and the residue was washed with cold methanol, and then chloroform to give 0.1 g (84%) of product. This material had melting point 167°-168°C [Prelog, supra] and was identical to an authentic sample by 300 MHz NMR [sample of deferrioxamine B supplied by dr. Heirich H. Peter at Ciba-Geigy, Basel, Switzerland].

brand name

Desferal (Novartis).

Therapeutic Function

Pharmaceutic aid (chelating agent)

Environmental Fate

Localized infusion or injection site reactions may occur with deferoxamine administration, such as pain, urticaria and flushing of the skin. Hypersensitivity reactions have been documented with both acute and chronic administration of deferoxamine. Some of the more serious side effects include infusion rate-related hypotension, renal insufficiency, neurotoxicity, growth retardation, pulmonary toxicity, and infections. Deferoxamine may induce venous dilation when given at doses greater than 15 mg kg-1 h-1 leading to poor venous return, depressed cardiac output, and eventually hypotension. Increased levels of histamine have been noted during hypotensive episodes, although pretreatment with antihistamines has not been shown to stop the reaction. An acute decrease in glomerular filtration rate and renal plasma flow secondary to hypotension is the possible mechanism underlying the nephrotoxicity induced by deferoxamine. Depletion of iron, translocation of copper, and chelation of other trace elements including zinc may interfere with critical iron-dependent enzymes, causing oxidative damage within various tissues. These are possible mechanisms thought to be responsible for deferoxamineinduced neurotoxicity, growth retardation, and pulmonary toxicity. In vitro studies have shown that deferoxamine inhibits the synthesis of prostaglandin, hemoglobin, ferritin, collagen, and DNA. The iron–deferoxamine complex, ferrioxamine, is a growth factor for many bacteria and fungi. Deferoxamine has been associated with Yersinia enterocolitica overgrowth and fatal cases of mucormycosis with prolonged therapy.

Deferoxamine Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Deferoxamine Suppliers

ChemStrong Scientific Co.,Ltd
Tel
0755-0755-66853366 13670046396
Fax
0755-28363542
Email
sales@chem-strong.com
Country
China
ProdList
18070
Advantage
56
Shanghai Macklin Biochemical Co.,Ltd.
Tel
15221275939 15221275939
Fax
021-50706099
Email
shenlinxing@macklin.cn
Country
China
ProdList
16166
Advantage
55
Chizhou Kailong Import and Export Trade Co., Ltd.
Tel
Fax
-
Email
xg01_gj@163.com
Country
China
ProdList
9484
Advantage
50
Shanghai Synchem Pharma Co., ltd
Tel
21-619849051-1 18521059765
Email
synchempharma@aliyun.com
Country
China
ProdList
6463
Advantage
55
ShangHai Biochempartner Co.,Ltd
Tel
177-54423994 17754423994
Fax
QQ:2853530913
Email
2853530910@QQ.com
Country
China
ProdList
8012
Advantage
62
Amadis Chemical Company Limited
Tel
571-89925085
Fax
0086-571-89925065
Email
sales@amadischem.com
Country
China
ProdList
131957
Advantage
58
Beijing OKA biological technology co., LTD
Tel
010-010-010-62971590 18548936886
Fax
010-62340519
Email
jack@oka-vip.com
Country
China
ProdList
6897
Advantage
58
Dayang Chem (Hangzhou) Co.,Ltd.
Tel
571-88938639 +8617705817739
Fax
+86-571-88938652,+86-571- 88492614
Email
info@dycnchem.com
Country
China
ProdList
52849
Advantage
58
Shaanxi Dideu Medichem Co. Ltd
Tel
+86-029-89586680 +86-18192503167
Fax
+86-29-88380327
Email
1026@dideu.com
Country
China
ProdList
7724
Advantage
58
Hubei Jusheng Technology Co.,Ltd.
Tel
18871490254
Fax
027-59599243
Email
linda@hubeijusheng.com
Country
CHINA
ProdList
28172
Advantage
58
Guangzhou Younan Technology Co., Ltd
Tel
020-82000279 18988968278
Fax
QQ:3283937693
Email
sales@ubiochem.com
Country
China
ProdList
4297
Advantage
58
Nanchang Tianzhen Biotechnology Co., Ltd
Tel
13173652190
Email
pomy@tanzhenbio.com
Country
China
ProdList
1785
Advantage
58
Wuhan Topule
Tel
+86-02787215551 +86-19945035818
Fax
027-87215551
Email
2936752263@qq.com
Country
China
ProdList
7977
Advantage
58
Mainchem Co., Ltd.
Tel
--
Fax
--
Email
sarah@mainchem.com
Country
China
ProdList
6567
Advantage
58
Zhengzhou Akem Chemical Co., Ltd
Tel
13303867194
Email
3001317055@qq.com
Country
China
ProdList
9962
Advantage
58
Hubei Kele Fine Chemical Co., Ltd
Tel
027-59101668 19945030958
Fax
027-59101668
Email
2881924765@qq.com
Country
China
ProdList
7890
Advantage
58
Wuhan Augda Biotechnology Co., Ltd
Tel
15071299552
Fax
QQ:262933239
Email
262933239@qq.com
Country
China
ProdList
6887
Advantage
58
Beijing Taihe Jingming Pharmaceutical Technology Co., Ltd.
Tel
15011440205
Email
chem_w@163.com
Country
China
ProdList
304
Advantage
58
Shaanxi DIDU pharmaceutical and Chemical Co., Ltd
Tel
15229059051
Email
1027@dideu.com
Country
China
ProdList
10003
Advantage
58
Wuhan Yingnuo Pharmaceutical Technology Co., Ltd.
Tel
+86-027-59232304 15387063101
Email
2881924050@qq.com
Country
China
ProdList
9956
Advantage
58
TargetMol Chemicals Inc.
Tel
4008200310
Email
marketing@tsbiochem.com
Country
China
ProdList
24644
Advantage
58
Xianning Shen Lan Biomedical Research and Development Co., Ltd.
Tel
18171815831
Email
1341138380@qq.com
Country
China
ProdList
3401
Advantage
58
Accela ChemBio Co.,Ltd.
Tel
021-50795510 4000665055
Email
SY06@accelachem.com
Country
China
ProdList
8118
Advantage
58
Beijing Taihe Jingming Pharmaceutical Technology Co., Ltd
Tel
15011440205
Email
2053813258@qq.com
Country
China
ProdList
372
Advantage
58
RD International Technology Co., Limited
Tel
18024082417
Email
market@ubiochem.com
Country
China
ProdList
9266
Advantage
58
Olix (Shanghai) Pharmaceutical Technology Co., Ltd
Tel
17316404525
Email
209533805@qq.com
Country
China
ProdList
9765
Advantage
58
Henan Tianfu Chemical Co.,Ltd.
Tel
+86-0371-55170693 +86-19937530512
Fax
0371-55170693
Email
info@tianfuchem.com
Country
China
ProdList
21634
Advantage
55
Wuhan Jingkang en Biomedical Technology Co., Ltd
Tel
+8613720134139
Email
orders@jknbiochem.com
Country
China
ProdList
5221
Advantage
58
Wuhan Topule Biopharmaceutical Co., Ltd
Tel
+8618327326525
Email
masar@topule.com
Country
China
ProdList
8467
Advantage
58
GIHI CHEMICALS CO.,LIMITED
Tel
+8618058761490
Email
info@gihichemicals.com
Country
China
ProdList
49978
Advantage
58
PT CHEM GROUP LIMITED
Tel
+86-85511178; +86-85511178;
Email
peter68@ptchemgroup.com
Country
China
ProdList
35425
Advantage
58
Shanghai Hao Zhun Biological Technology Co., Ltd.
Tel
--
Fax
--
Email
info@zzsrm.com
Country
CHINA
ProdList
6650
Advantage
58
Taizhou Hikong Chemical Co., Ltd.
Tel
--
Fax
--
Country
China
ProdList
52
Advantage
50
Nanjing Xianhang Medical Technology Co., Ltd.
Tel
--
Fax
--
Country
China
ProdList
47
Advantage
60
Shanghai Mokai Pharmaceutical Co., Ltd.
Tel
--
Fax
--
Email
yl@mkpharma.cn
Country
China
ProdList
317
Advantage
50
Shandong Zibo Dingjin Chemical Co., Ltd
Tel
--
Fax
--
Country
China
ProdList
57
Advantage
64
Lanospharma Laboratories Co.,Ltd
Tel
--
Fax
--
Email
sales@lanospharma.com
Country
China
ProdList
6329
Advantage
56
Yick-Vic Chemicals & Pharmaceuticals (HK) Ltd
Tel
--
Fax
--
Email
sales@yickvic.com
Country
China
ProdList
6206
Advantage
58
More
Less

View Lastest Price from Deferoxamine manufacturers

Shaanxi Dideu Medichem Co. Ltd
Product
Deferoxamine 70-51-9
Price
US $1.10/g
Min. Order
1g
Purity
99.0% min
Supply Ability
100 tons min
Release date
2021-05-25
Wuhan Topule Biopharmaceutical Co., Ltd
Product
Deferoxamine 70-51-9
Price
US $8.00/mg
Min. Order
10mg
Purity
98%
Supply Ability
50g
Release date
2023-06-13

70-51-9, DeferoxamineRelated Search:


  • deferoxamideb
  • deferoxamin
  • deferoxamine
  • deferoxamineb
  • deferoxaminum
  • deferrioxamine
  • deferrioxamineb
  • desferan
  • desferex
  • desferin
  • desferral
  • desferriferrioxaminb
  • desferrin
  • desferrioxamineb
  • dfoa
  • entaone
  • n-[5-[3-[(5-aminopentyl)hydroxycarbamoyl]propionamido]pentyl]-3-[[5-(n-hydroxy
  • n’-[5-[[4-[[5-(acetylhydroxamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pen
  • n-benzoyl-ferrioxamine
  • n-benzoylferrioxamineb
  • nsc-527604
  • ButanediaMide,N4-[5-[[4-[[5-(acetylhydroxyaMino)pentyl]aMino]-1,4-dioxobutyl]hydroxyaMino]pentyl]-N1-(5-aMinopentyl)-N1-hydroxy-
  • 1-amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(n-acetylhydroxylamino)-6,11,17,
  • 22-tetraazaheptaeicosane
  • 3,9,14,20,25-pentaazatriacontane-2,10,13,21,24-pentone,30-amino-3,14,25-trih
  • 3,9,14,20,25-pentaazatriacontane-2,10,13,21,24-pentone,30-amino-3,14,25-trihyd
  • 30-amino-3,14,25-trihydroxy-3,9,14,20,25-pentaazatriacontane-2,10,13,21,24-p
  • 30-amino-3,14,25-trihydroxy-3,9,14,20,25-pentaazatriacontane-2,10,13,21,24-pen
  • acetamido)pentyl]carbamoyl]propionohydroxamicacid
  • ba-29837
  • ba33112
  • ba-33112
  • butanediamide,n’-(5-((4-((5-(acetylhydroxyamino)pentyl)amino)-1,4-dioxobutyl)h
  • pentyl)-3-((5-(n-hydroxyacetamido)pentyl)carbamoyl)-
  • taone
  • tyl]-n-(5-aminopentyl)-n-hydroxybutanediamide
  • ydroxyamino)pentyl)-n-(5-aminopentyl)-n-hydroxy-
  • N-[5-[[4-[5-azanylpentyl(hydroxy)amino]-4-oxo-butanoyl]amino]pentyl]-N'-[5-[ethanoyl(hydroxy)amino]pentyl]-N-hydroxy-butanediamide
  • N'-[5-[acetyl(hydroxy)amino]pentyl]-N-[5-[[4-[5-aminopentyl(hydroxy)amino]-4-keto-butanoyl]amino]pentyl]-N-hydroxy-succinamide
  • N'-[5-[acetyl(hydroxy)amino]pentyl]-N-[5-[[4-[5-aminopentyl(hydroxy)amino]-4-oxobutanoyl]amino]pentyl]-N-hydroxybutanediamide
  • N1-(5-Aminopentyl)-N1-hydroxy-N4-(5-(N-hydroxy-4-((5-(N-hydroxyacetamido)-pentyl)amino)-4-oxobuta
  • DESFEROXAMINE
  • DESFERROXAMINE
  • N'-[5-[[4-[[5-(Acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N-(5-aminopentyl)-N-hydroxysuccinamide
  • N'-{5-[ACETYL(HYDROXY)AMINO]PENTYL}-N-[5-({4-[(5-AMINOPENTYL)(HYDROXY)AMINO]-4-OXOBUTANOYL}AMINO)PENTYL]-N-HYDROXYSUCCINAMIDE
  • N1-(5-aminopentyl)-N1-hydroxy-N4-(5-(N-hydroxy-4-((5-(N-hydroxyacetamido)pentyl)amino)-4-oxobutanamido)pentyl)succinamide
  • Deferoxamine USP/EP/BP
  • Deferoxamine B|||Desferrioxamine B
  • 70-51-9
  • C25H48N6O8